Last Posted: Nov 21, 2019
- Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
Oliveira Douglas Nogueira Perez et al. PloS one 2019 (11) e0225249 - Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
Dekanek Erin W et al. Journal of genetic counseling 2019 Nov - Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers.
Matsubayashi Hiroyuki et al. Diagnostics (Basel, Switzerland) 2019 Oct 9(4) - Chlamydia trachomatis and human herpesvirus 6 infections in ovarian cancer-Casual or causal?
Gulve Nitish et al. PLoS pathogens 2019 Nov (11) e1008055 - Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
Conley Claire C et al. Annals of surgical oncology 2019 Nov - Survey of primary care physicians' views about breast and ovarian cancer screening for true BRCA1/2 non-carriers.
Pelletier S et al. Journal of community genetics 2019 Oct - CMS Aims to Broaden Coverage for NGS Testing in Breast, Ovarian Cancer -Expansion would include patients with risk factors for inherited susceptibility mutations
I Ingram, MedPage Today, October 31, 2019 - Year in Review: Ovarian Cancer: PARP inhibitors, genetic testing, and novel combinations
I Ingram, Medpage Today, November 1, 2019 - The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
Kubelac Paul et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 24(4) 1538-1543 - PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
NCI, October 29, 2019
.png)
No hay comentarios:
Publicar un comentario